DA-8159, a New PDE5 Inhibitor, Attenuates the Development of Compensatory Right Ventricular Hypertrophy in a Rat Model of Pulmonary Hypertension

Author： Kang KK   Ahn GJ   Sohn YS   Ahn BO   Kim WB  

Publisher： Field House Publishing

ISSN： 0300-0605

Source： The Journal of International Medical Research, Vol.31, Iss.6, 2003-11, pp. : 517-528

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chronic infusion of adrenomedullin reduces pulmonary hypertension and lessens right ventricular hypertrophy in rats administered monocrotaline

By Yoshihara F.   Nishikimi T.   Horio T.   Yutani C.   Takishita S.   Matsuo H.   Ohe T.   Kangawa K.  

European Journal of Pharmacology, Vol. 355, Iss. 1, 1998-08 ,pp. : 33-39

Elsevier

Access to resources Recommend Favorite

Left Ventricular Hypertrophy in Hypertension

By  

Heart Drug, Vol. 2, Iss. 5, 2003-01 ,pp. : 251-265

Karger

Access to resources Recommend Favorite

Left Ventricular Hypertrophy in Hypertension

By  

Heart Drug, Vol. 2, Iss. 3, 2002-07 ,pp. : 142-156

Karger

Access to resources Recommend Favorite

Energetic Metabolic Roles in Pulmonary Arterial Hypertension and Right Ventricular Remodeling

By  

Current Pharmaceutical Design, Vol. 22, Iss. 31, 2016-09 ,pp. : 4780-4795

Bentham Science Publishers

Access to resources Recommend Favorite

The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS

By Guerard Pascal   Rakotoniaina Zo   Goirand Françoise   Rochette Luc   Dumas Monique   Lirussi Frederic   Bardou Marc  

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 373, Iss. 6, 2006-09 ,pp. : 401-414

Springer Publishing Company

Access to resources Recommend Favorite